Key result
Higher serum Cystatin C levels were significantly associated with an increased 10-year estimated risk for coronary heart disease, rising from 13.1% in the lowest quartile to 35.4% in the highest.
Why the study?
Is serum Cystatin C associated with cardiovascular biomarkers and estimated 10-year cardiovascular risk in type 2 diabetic patients?
Cross-Sectional (n=520)
No
Is serum Cystatin C associated with cardiovascular biomarkers and estimated 10-year cardiovascular risk in type 2 diabetic patients?
Absolute Event Rate: 35.4% vs 13.1%
p-value: p=<0.0001
Cystatin C levels significantly correlate with emerging cardiovascular biomarkers and calculated 10-year cardiovascular risk in patients with type 2 diabetes.
May support Cystatin C for CHD risk assessment in type 2 diabetes; leaves open its added value in prospective cohorts.
Background: Recent studies suggest that serum Cystatin C is both a sensitive marker for renal dysfunction and a predictive marker for cardiovascular diseases.We aimed to evaluate the association between Cystatin C and various biomarkers and to find out its utility in estimating risk for cardiovascular diseases in type 2 diabetic patients.Methods: From June 2006 to March 2008, anthropometric measurements and biochemical studies including biomarkers for risk factors of cardiovascular diseases were done in 520 type 2 diabetic patients.A 10-year risk for coronary heart diseases and stroke was estimated using Framingham risk score and UKPDS risk engine.Results: The independent variables showing statistically significant associations with Cystatin C were age (β = 0.009, P < 0.0001), hemoglobin (β = -0.038,P = 0.0006), serum creatinine (β = 0.719, β < 0.0001), uric acid (β = 0.048, P = 0.0004), log hsCRP (β = 0.035, P = 0.0021) and homocysteine (β = 0.005, P = 0.0228).The levels of microalbuminuria, carotid intima-media thickness, fibrinogen and lipoprotein (a) also correlated with Cystatin C, although the significance was lost after multivariate adjustment.Calculated risk for coronary heart diseases increased in proportion to Cystatin C quartiles: 3.3 ± 0.4, 6.2 ± 0.6, 7.6 ± 0.7, 8.4 ± 0.7% from Framingham risk score (P < 0.0001); 13.1 ± 0.9, 21.2 ± 1.6, 26.1 ± 1.7, 35.4 ± 2.0% from UKPDS risk engine (P < 0.0001) (means ± SE).Conclusions: Cystatin C is significantly correlated with various emerging biomarkers for cardiovascular diseases.It was also in accordance with the calculated risk for cardiovascular diseases.These findings verify Cystatin C as a valuable and useful marker for predicting future cardiovascular diseases in type 2 diabetic patients.(
No takes yet. Share an insight, caveat, or question.
Lee et al. (2008) conducted a cross-sectional in Type 2 diabetes (n=520). Serum Cystatin C vs. Lower Cystatin C quartiles was evaluated on 10-year risk for coronary heart disease estimated by UKPDS risk engine (p=<0.0001). Higher serum Cystatin C levels were significantly associated with an increased 10-year estimated risk for coronary heart disease, rising from 13.1% in the lowest quartile to 35.4% in the highest.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: